HS-10502 + platinum + bevacizumab

HS-10502 + platinum + bevacizumab is a combination therapy under investigation for the treatment of advanced solid tumors. HS-10502 is an orally bioavailable, selective inhibitor of poly(ADP-ribose) polymerase 1 (PARP1), which blocks DNA repair via the base excision repair pathway, leading to increased DNA damage and potential cancer cell death. Platinum agents are a class of chemotherapeutic drugs that cause DNA crosslinking and apoptosis, while bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis in tumors. This combination aims to enhance antitumor efficacy by simultaneously impairing DNA repair, inducing cytotoxicity, and blocking tumor blood vessel formation. The regimen is being developed primarily by Jiangsu Hansoh Pharmaceutical for use in various advanced solid malignancies including recurrent ovarian cancer, HER2-negative advanced breast cancer, triple-negative breast cancer (TNBC), advanced prostate cancer, and advanced gastric cancer[1][3][4][5][7].